• slide 1 slide 1

    Slide 1 Title

    Slide 1 description

    Slide 1 CTA

    Slide 1 Caption

  • Slide 2 Slide 2

    Slide 2 title

    Slide 2 description

    PDF

    Slide 2 Caption

  • Slide 3 Slide 3

    Slide 3 Title

    Slide 3 caption

  • Slide 4 Slide 4
  • ${_.imageAltText5} ${_.imageAltText5}

    Slide Title 1

    CTA 5
of
  • slide 1 slide 1

    Slide 1 Title

    Slide 1 description

    Slide 1 CTA

    Slide 1 Caption

  • Slide 2 Slide 2

    Slide 2 title

    Slide 2 description

    PDF

    Slide 2 Caption

  • Slide 3 Slide 3

    Slide 3 Title

    Slide 3 caption

  • Slide 4 Slide 4
  • ${_.imageAltText5} ${_.imageAltText5}

    Slide Title 1

    CTA 5
of
lung

Tasso annualizzato di riacutizzazioni moderate/severe:
Differenza nei tassi di incidenza (IR) per tutti gli studi.
Differenza negli IR per gli studi con ≥24 settimane di follow-up

FF/UMEC/VI 100/62,5/25 μg QD con singolo erogatore

Our Eosinophilosophy

EOS counts in severe Eosinophilic Asthma

Severe asthma with eosinophilic phenotype is a distinct phenotype of severe asthma. This phenotype is characterized by airway inflammation, increased eosinophil levels, poor asthma control, and increased rate of exacerbations.1

Half of severe asthma patients have persistent airway tissue eosinophils resulting in poor prognosis and frequent exacerbations.2

IL-4

  • Macrophage polarization

IL-4

  • Macrophage polarization

IL-4

  • Macrophage polarization

IL-4

  • Macrophage polarization

Elevated EOS are associated with asthma exacerbations10,11

Patients with asthma and blood eosinophils ≥300 cells/μL and fractional exhaled nitric oxide (FeNO) ≥50 ppb were nearly 4x more likely to have a severe exacerbation than those with lower blood eosinophils (<300 cells/μL) and low FeNO (<25 ppb).10 Intermediate and high blood eosinophils were associated with asthma-related visits to the emergency department.11

IL-4

  • Macrophage polarization

IL-4

  • Macrophage polarization
test

EOSINOPHILS/𝝻L

Knowing your severe asthma patients’ eosinophil count can help you give them a more targeted treatment13

test

Cardiovascular/cerebrovascular disease

test

Cardiovascular/cerebrovascular disease

test

Cardiovascular/cerebrovascular disease

Find out more about the product

Explore why EOS counts in different disease states

Other lung conditions

Open

Other lung conditions

open

IL-4

  • Macrophage polarization

IL-4

  • Macrophage polarization

IL-4

  • Macrophage polarization

IL-4

  • Macrophage polarization

Copenhagen, Denmark

ECCMID

April 15 – 18, 2023

Symposium Recording

Symposium review article by EMJ

Posters

Podcast Test

Lung function (FEV1)

test

Lung function (FEV1)

test
Product
Terrenae
Recens

 

Summary of key data

Efficacy4,16
  • In Study 006, the first season analysis demonstrated that RSVPreF3 OA provides high and consistent efficacy against the full spectrum of RSV disease regardless of RSV subtype in adults ≥60 years of age
  • Efficacy over an entire RSV season: (based on Season 1 analysis)

82.6%

RSV-LRTD
(≥60 YOA)

94.1%

Severe RSV-LRTD
(≥60 YOA)

94.6%

RSV-LRTD
(≥1 comorbidity of interest*)
  • One dose of RSVPreF3 OA vaccine provides durable efficacy against RSVassociated LRTD for 2 full RSV seasons, including against severe RSV disease, in adults with underlying comorbidities, and across advancing ages
Immune Response16–18
  • RSVPreF3 OA induces a robust and persistent humoral and T-cell immune response
  • Co-administered with FLU-QIV, FLU-QIV-HD, or FLU-aQIV without evidence of clinically meaningful interference
Safety4,16,18,19
  • RSVPreF3 OA vaccine is well tolerated with an acceptable safety profile
test
FLU-QIV: ≥60 years of age (YOA) (N=890)1,5
 FLU-QIV-HD: ≥65 YOA (N=1028)2
 FLU-aQIV: ≥65 YOA (N=1045)3

Local

  • Lorem ipsum dolor sit amet, consectetur adipiscing elit. Proin at metus purus. Proin eu nunc vitae orci efficitur laoreet.

Maecenas at nibh tortor. Vivamus cursus purus arcu, et tristique eros ornare quis. Suspendisse eget viverra odio, vel euismod justo. Vestibulum a elit sapien. Curabitur varius nunc in mi bibendum bibendum.

test

Local

test

Test

Open

Open

PDF

Test

Read more